Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Nine Months Ended September 30, 2017

XIANYANG, China, Nov. 20, 2017 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for third quarter ended September 30, 2017.

During the third fiscal quarter of 2017, the Company recognized:

No net sales, a decrease of approximately $0.6 million or 100% as compared to the same period in 2016.
No gross profit, a decreased of approximately $0.3 million or 100% as compared to the same period in 2016.
Net loss of $0.1 million as compared to net loss of $1.6 million for the same period in 2016.

The Company had no sales on all Aoxing Pharmaceutical products in the third fiscal quarter ended September 30, 2017 as Aoxing Pharmaceutical temporarily stopped production to conduct maintenance of its production lines to renew its GMP certificates. The application for the renewal of Aoxing Pharmaceutical's GMP certificates has been preliminarily approved and publicly announced by the local government in October 2017, subject to the final approval to be granted before the end of 2017, at which time the production is expected to resume. There is no assurance that the production lines at Aoxing will resume as and when expected and that the GMP certificates will be renewed as and when anticipated, or even if such certificates are renewed, the Company will be able to return to the anticipated production levels, which, in turn, may have material adverse effects on the Company's business, operations, financial performance and value of its securities. The Company also had no sales on Shaanxi Weinan's products during the second quarter of 2017 due to replacing production equipment to comply with government's environmental protection requirements. The Company currently anticipates resuming the production of Shaanxi Weinan production lines before the end of 2017. The above-referenced suspensions of the Company's production lines have materially negatively affected the Company's operating results; as a result, there may be substantial doubt regarding the Company's ability to continue as a going concern. If the Company is unable to renew its GMP certificates and resume production as and when anticipated, its operations will be materially negatively affected and the Company might become insolvent, and the Company's revenues, operations and the value of its common stock and common stock equivalents would be materially negatively impacted; the Company may substantially curtail or cease its operations.

*The Company's Condensed Consolidated Balance Sheets, Statement of Operations, and Cash Flows can be found at the end of this press release. Please also refer the Company's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission for further information regarding the Company's results of operations, including updated risk factors facing the Company.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures, and markets pharmaceutical and health supplement products for a variety of diseases and conditions. For more information please visit: http://www.biostarpharmaceuticals.com.

Safe Harbor Relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company's ability to complete the GMP certification renewal process in the time frame as and when currently anticipated, the Company's ability to resume production as and when anticipated, its ability to resume and sustain its sales effort going forward, its ability promptly and effectively to return to the normal production levels, its ability to retain existing and retain new customers for its products, its ability to achieve the projected sales through the efforts of the call center, to complete the contemplated clinical trials and capitalize on such opportunities, the Company's ability to recover its sales and revenue following the repair and maintenance for GMP certification renewal, the state of consumer confidence and market demand or the Company's products, success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2016, and other subsequent filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

Investor Relations Contact

Please send questions or comments to:

Biostar Pharmaceuticals, Inc.

Investor Relations Coordinator

+86-29-3368-6638

office@aoxing-group.com

http://www.biostarpharmaceuticals.com

BIOSTAR PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS

	September 30,		December 31,
	2017		2016
	(Unaudited)
ASSETS

Current Assets
Cash and cash equivalents	$	364,973	$	173,290
Accounts receivable, net		-		6,741,454
Inventories		170,555		166,564
Deposits and other receivables		335,183		171,062
Value-added tax recoverable		51,526		41,462
Income tax recoverable		74,402		71,292
Total Current Assets		996,639		7,365,124

Non-current Assets
Deposits		26,579,097		21,148,284
Deferred tax assets, net		2,625,001		2,515,272
Property and equipment, net		5,845,985		5,866,612
Intangible assets, net		5,380,544		5,607,146
Total Non-Current Assets		40,430,627		35,137,314

Total Assets	$	41,427,266	$	42,502,438


LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities
Accounts and other payables	$	2,686,200	$	2,842,142
Short-term bank loans		2,427,098		2,325,643
Warrants liability		166,145		455,476
Total Current Liabilities		5,279,443		5,623,261

Commitment and contingencies

Stockholders' Equity
Common stock, $0.001 par value, 100,000,000 shares authorized, 2,637,188 shares issued and outstanding as of September 30, 2017 and December 31, 2016		2,637		2,637
Additional paid-in capital		31,382,467		31,382,467
Statutory reserve		7,354,413		7,354,413
Accumulated deficit		(4,994,713)		(2,540,991)
Accumulated other comprehensive income		2,403,019		680,651
Total Stockholders' Equity		36,147,823		36,879,177

Total Liabilities and Stockholders' Equity	$	41,427,266	$	42,502,438

BIOSTAR PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)

	Three months ended September 30,				Nine months ended September 30,
	2017		2016		2017		2016

Sales, net	$	-	$	644,933	$	-	$	2,066,698
Cost of sales		-		336,870		-		1,114,777
Gross profit		-		308,063		-		951,921

Operating expenses:
Selling expenses		14,668		290,924		300,352		904,037
General and administrative expenses		558,713		488,136		2,840,865		1,717,992
Provision for doubtful debt		-		1,491,002		-		7,820,713
Total operating expenses		573,381		2,270,062		3,141,217		10,442,742

Loss from operations		(573,381)		(1,961,999)		(3,141,217)		(9,490,821)

Other income (expense):
Interest income		13		-		1,321		-
Interest expense		(47,209)		(105,401)		(138,831)		(143,716)
Fair value adjustment on warrants		12,925		2,151		289,331		46,499
Other income		482,466		501,578		535,674		501,578
Total other income, net		448,195		398,328		687,495		404,361

Loss before income taxes		(125,186)		(1,563,671)		(2,453,722)		(9,086,460)

Income tax expenses		-		-		-		-

Net loss	$	(125,186)	$	(1,563,671)	$	(2,453,722)	$	(9,086,460)

Foreign currency translation adjustment		786,669		(174,104)		1,722,368		(1,152,031)

Comprehensive loss	$	661,483	$	(1,737,775)	$	(731,354)	$	(10,238,491)

Net loss per share
Basic	$	(0.05)	$	(0.71)	$	(0.93)	$	(4.11)
Diluted	$	(0.05)	$	(0.71)	$	(0.93)	$	(4.11)

Weighted average number of common shares outstanding
Basic		2,637,188		2,210,913		2,637,188		2,210,913
Diluted		2,637,188		2,210,913		2,637,188		2,210,913

BIOSTAR PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

	Nine Months Ended September 30,
	2017		2016
CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES
Net loss	$	(2,453,722)	$	(9,086,460)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		879,845		913,394
Provision for doubtful accounts		-		7,820,713
Fair value adjustment on warrants		(289,331)		(46,499)
Changes in operating assets and liabilities:
Accounts receivable		6,879,240		1,605,000
Inventories		3,203		(214,017)
Deposits and other receivables		(153,182)		-
Accounts payable and accrued expenses		(272,433)		52,903
Value-added tax payable		(8,073)		(133,977)
Net cash provided by operating activities		4,585,547		911,057

CASH FLOWS USED IN INVESTING ACTIVITIES
Deposit paid to intended acquisition		(4,408,070)		-
Net cash used in investing activities		(4,408,070)		-

CASH FLOWS USED IN FINANCING ACTIVITIES
Repayment of short-term bank loans		-		(281,016)
Net cash used in financing activities		-		(281,016)

Effect of exchange rate changes on cash and cash equivalents		14,206		(9,580)

Net increase in cash and cash equivalents		191,683		620,461

Cash and cash equivalents, beginning balance		173,290		38,898
Cash and cash equivalents, ending balance	$	364,973	$	659,359

SUPPLEMENTAL DISCLOSURES:
Interest received	$	1,321	$	-
Interest paid	$	-	$	(143,716)

DC81799269.1

View original content:http://www.prnewswire.com/news-releases/biostar-pharmaceuticals-inc-announces-its-quarterly-results-for-nine-months-ended-september-30-2017-300559151.html

SOURCE Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals (CE) (USOTC:BSPM)
Historical Stock Chart
From Nov 2024 to Dec 2024